Business
Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer’s Disease
VANCOUVER, British Columbia & DALLAS, March 18, 2025--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced the official commercial launch of ZUNVEYL, a new treatment for mild to moderate Alzheimer’s disease. This milestone marks a major step forward in the company’s mission to provide innovative and accessible solutions for patients and caregivers — and to deliver new hope to the millions impacted by Al
About this update from Alpha Cognition Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1402,"height":504,"url":"https://media.zenfs.com/en/business-wire.com/74129fd2eba3c78edfb23ec86183627d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/K91GbrLbZmpvjnbEQnQBuw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM0NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/74129fd2eba3c78edfb23ec86183627d","width":960,"height":345},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/t14T3MOdzWN9Cv1pKFfSZg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04NjI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/74129fd2eba3c78edfb23ec86183627d","width":1200,"height":431}},"lazy":false},{"type":"text","content":"ZUNVEYL is the first oral FDA-approved treatment for Alzheimer’s disease in the past decade","length":91,"tagName":"p","attribs":{}},{"type":"text","content":"32 person sales team hired to cover the $2 billion Long-Term-Care market","length":72,"tagName":"p","attribs":{}},{"type":"text","content":"All launch activities delivered on-time and on-budget, positioning ZUNVEYL for success","length":86,"tagName":"p","attribs":{}},{"type":"text","content":"VANCOUVER, British Columbia & DALLAS, March 18, 2025--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced the official commercial launch of ZUNVEYL, a new treatment for mild to moderate Alzheimer’s disease. This milestone marks a major step forward in the company’s mission to provide innovative and accessible solutions for patients and caregivers — and to deliver new hope to the millions impacted by Alzheimer’s.","length":531,"tagName":"p"},{"type":"text","content":"With a highly experienced commercial team in place, including industry leaders with proven success in the long-term care market, Alpha Cognition is poised to make a powerful impact. The company’s nationwide salesforce is fully deployed and actively engaging with healthcare providers to ensure that ZUNVEYL reaches the patients who need it most. The commercial strategy is specifically designed to address the unique challenges of the long-term care market, the largest segment for Alzheimer’s disease, and a $2 billion market opportunity.","length":539,"tagName":"p"},{"type":"text","c...